不同病理分期乳腺癌患者免疫功能、肿瘤标志物及炎症因子的变化分析

Changes of immune function, tumor markers and inflammatory factors in breast cancer patients with different pathological stages

目的:探讨不同病理分期乳腺癌患者免疫功能、肿瘤标志物及炎症因子的水平变化。方法:选取我院收治的120例乳腺癌患者作为研究对象,根据TNM分期分为I期31例,Ⅱ期36例,Ⅲ期28例,IV期25例,另选取同期于我院体检的50例健康女性作为对照组,检测并比较各组对象的免疫功能、肿瘤标志物及炎症因子水平。结果:对照组的CD3^+、CD4^+、CD4^+/CD8^+水平高于各期乳腺癌患者,对照组的CD8^+水平低于各期乳腺癌患者,差异均有统计学意义(P<0.05);随着病理分期的升高,CD3^+、CD4^+、CD4^+/CD8^+水平逐渐降低,CD8^+水平逐渐升高,差异均有统计学意义(P<0.05)。对照组的IgG、IgM水平均低于各期乳腺癌患者,差异均有统计学意义(P<0.05);随着病理分期的升高,IgG、IgM水平逐渐升高,差异均有统计学意义(P<0.05)。对照组CEA、CA125、CA153水平均低于各期乳腺癌患者,差异均有统计学意义(P<0.05);随着病理分期的升高,CEA、CA125、CA153水平逐渐升高,差异均有统计学意义(P<0.05)。对照组TNF-α、hs-CRP水平均低于各期乳腺癌患者,差异均有统计学意义(P<0.05);随着病理分期的升高,TNF-α、hs-CRP水平逐渐升高,差异均有统计学意义(P<0.05)。结论:不同病理分期乳腺癌患者的免疫功能、肿瘤标志物及炎症因子水平各不相同,检测相关指标可为监控病理进展、评估病情变化提供科学依据。

Objective: To investigate the changes of immune function, tumor markers and inflammatory factors in breast cancer patients with different pathological stages. Methods: From January 2017 to June 2018, 120 patients with breast cancer in our hospital were selected as subjects. According to TNM staging, they were divided into stage I (31 cases), stage Ⅱ(36 cases), stage Ⅲ(28 cases) and stage IV (25 cases). Another 50 healthy women in our hospital during the same period were selected as control group. The immune function, tumor markers and inflammatory factors in each group were detected and compared. Results: The levels of CD3^+, CD4 +, CD8 +, CD4^+/CD8^+ in the control group were (67.38±4.41)%,(51.38± 2.59)%,(21.88±2.26)%,(2.33±0.34), respectively. The levels of CD3^+, CD4^+, CD4^+/CD8^+ in the control group were higher than those in the breast cancer patients of all stages, and the level of CD8^+ in the control group was lower than those in the breast cancer patients of all stages ( P <0.05);The levels of CD3^+, CD4^+, CD4^+/CD8^+ gradually decreased and the levels of CD8 + gradually increased with the increase of pathological stage ( P <0.05). The levels of IgG and IgM in the control group were (7.03±1.27) g/L and (1.20±0.40) g/L respectively, which were lower than those in the patients with breast cancer of all stages ( P <0.05). With the increase of pathological stages, the levels of IgG and IgM increased gradually ( P <0.05). The levels of CEA, CA125 and CA153 in the control group were (1.54±0.53)μg/L,(12.53±2.26) U/mL and (7.63±1.67) U/mL, respectively, which were lower than those in the patients with breast cancer of all stages ( P <0.05). The levels of CEA, CA125 and CA153 gradually increased with the increase of pathological stages ( P <0.05). The levels of TNF-α and hs-CRP in the control group were (73.32±10.57) pg/L and (2.24±0.43) mg/L, respectively, which were lower than those in the patients with breast cancer of all stages ( P <0.05). The levels of TNF-α and hs-CRP increased gradually with the increase of pathological stages ( P <0.05). Conclusion: The levels of immune function, tumor markers and inflammatory factors are different in different pathological stages of breast cancer. Detection of relevant indicators can provide a scientific basis for monitoring pathological progress and evaluating disease changes.